Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting

Bristol Myers Squibb’s (NYSE:BMY) Opdivo (nivolumab) and Merck’s (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the treatment of various types of cancer, will be the focus of a U.S. FDA advisory panel on Sept. 26.

The purpose